Posts for Ticker ‘VICL’

Top Day Trader Alerts (C, RPRX, AAI, AVNR, AA, LINE, VICL)

These are this Wednesday morning’s top day trader and active trader stocks with price and volume moves.  More detailed price and volume analysis has been provided with a link to each stock story over at VSInvestor.com:

Citigroup (NYSE: C) is lower by less than 1% on what seemed like decent news.

Repros Therapeutics Inc. (NASDAQ: RPRX) is up over 100% on huge volume.

AirTran Holdings Inc. (NYSE: AAI) is down over 12% on a secondary offering announcement.

AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) is up over 6% on a patent allowance to treat pseudobulbar affect, which the company says there are no treatments on the market yet.

Alcoa Inc. (NYSE: AA) was very active in stock options late yesterday ahead of today’s earnings report.  We’d look for a continuation of that today as traders take deleveraged bets after such a large run up in the stock.

Linn Energy LLC (NASDAQ: LINE) is getting hit on high pre-market and also after-hours yesterday after it reported it would sell 6 million units in a secondary offering.

Vical Incorporated (NASDAQ: VICL) is trading up on positive Phase II trial data against CMV disease.

You can join our open email distribution list which goes out several times per week for reminders of the top day trader alerts, analyst upgrades and downgrades, IPO’s, key secondary offerings, guru investor data on Buffett and others, mergers, and more.

Jon C. Ogg

Posted on: October 7, 2009 – 9:00 am in After-Hours Activity, Pre-Market Activity, Trading Alert, , , , , , ,

Big Price Movers For The Day (CNXT)(HERO)(HLCS)(VICL)(AAPL)

For news and details on stocks that will be trading significantly up or down on volume, visit Volume Spike Investor.

Today’s coverage includes Hercules OffShore (HERO), Conexant (CNXT), Vical (VICL), and Helicos BioSciences (HLCS).

Apple (AAPL) is also moving on an accounting change that could help its earnings.

Douglas A. McIntyre

Posted on: September 24, 2009 – 8:54 am in Pre-Market Activity, , , , ,

Top Day Trader Alerts (SPSS, X, VICL, AMGN, ARIA, LCRD, DB, COH, CHKP)

The following are some of the top stocks to watch for active trading today based on pre-market and after-hours volume activity. There are links through to more detailed coverage and volume analysis at VSInvestor.com:

SPSS Inc (Nasdaq: SPSS) shares are up 41 percent after getting a $1.2 billion takeover offer from IBM.

United States Steel Corp. (NYSE: X) shares are falling in very active trade after it missed revenue expectations and said its outlook for overall steel demand remains uncertain.

Vical Inc. (Nasdaq: VICL) shares up strongly as one of the most active premarket issues after it received a direct investment.

Amgen Inc. (Nasdaq: AMGN) shares are seeing wishy-washy trading after earnings and a partnership.

Ariad Pharmaceuticals (Nasdaq: ARIA) are among the most active premarket stocks, following positive preliminary clinical data.

Deutsche Bank AG (NYSE: DB) shares are down 8 percent in very active premarket trading after reporting a larger provisions for credit losses.

Coach Inc. (NYSE: COH) shares are down more than 5 percent in the premarket on reporting earnings that were merely in line.

LaserCard Corp. (Nasdaq: LCRD) is among the biggest premarket percentage gainers after beating earnings expectations by 18 cents a share.

Check Point Software Technologies Ltd. (Nasdaq: CHKP) shares are rising in active premarket trade after beating EPS by 2 cents a share.

-The 24/7 Wall St. Team

Posted on: July 28, 2009 – 8:57 am in Pre-Market Activity, Trading Alert, , , , , , , , ,

Europe Steps Up Timetable On Swine Flu Vaccines (VICL, NVAX, BCRX)

earthShares of vaccine makers including Vical Inc. ((Nasdaq: VICL), Novavax Inc. (Nasdaq: NVAX) and BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) all are up strongly Monday after Europe’s version of the FDA decided to fast-track swine flu vaccine testing, making producers of the yet-to-be-approved inoculations potentially closer to bringing their products to market. Read More »

Posted on: July 27, 2009 – 10:53 am in Biotech, Drug companies, Pharmaceuticals, , ,

BioHealth Business Daily (AMGN, NVS, AMLN, LLY, ALKS, NVO, LLY, VICL, SCLN, ARNA)

These are some of the top stories affecting key drug and biotech stocks that are covered with more in-depth details and analysis this morning at BioHealthInvestor.com:

Amgen Inc’s (Nasdaq: AMGN)’s osteoporosis drug did so well in a head-to-head Phase III trial vs. the current standard drug from Novartis Inc. (NYSE:  NVS) that the Amgen’s drug may become the new standard for patients with breast cancer.

Amylin Pharmaceuticals Inc. (Nasdaq: AMLN), along with partners Eli Lilly & Co. (NYSE: LLY) and Alkermes Inc. (Nasdaq: ALKS), announced its new drug application for a once-weekly version of Byetta will be reviewed by the FDA, which may  help invigorate growth for the franchise.

Vical Inc. (Nasdaq: VICL) announced a positive four-month interim analysis for what is arguably its second-largest market opportunity, taking potentially another small step toward the goal of attracting a partner for its herpes vaccine program.

SciClone Pharmaceuticals Inc. (Nasdaq: SCLN) shares are down more than 7 percent on revenue and secondary offering fears. And Arena Pharmaceuticals Inc. (Nasdaq: ARNA) shares are falling after another dilutive offering.

Also, see our in-depth feature this week on five of the fastest-growing biotechs with improving analyst estimates: Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), Amicus Therapeutics Inc. (Nasdaq: FOLD), Halozyme Therapeutics Inc. (Nasdaq: HALO), American Oriental Bioengineering Inc. (NYSE: AOB), and Stemcells Inc. (Nasdaq: STEM).

-The 24/7 Wall St. Team

Posted on: July 8, 2009 – 9:47 am in Biotech, Drug companies, FDA, Medical, , , , , , , , ,

Top Analyst Upgrades (ARMH, ASML, BSX, CLX, GR, IFX, LAZ, SKS, SNIC, VICL)

These are some of the top pre-market analyst upgrades and positive research calls we have seen from Wall Street early this Friday morning with more than two hours until the market opens:

ARM Holdings (ARMH) Started as Overweight at Barclays.
ASML Holding (ASML) Started as Overweight at Barclays.
Boston Scientific (BSX) Started as Outperform at Baird.
Clorox (CLX) Raised to Outperform at Oppenheimer.
Goodrich (GR) Started as Outperform at Oppenheimer.
Infineon (IFX) Started as Overweight at Barclays.
Lazard (LAZ) Started as Outperform at Oppenheimer; removed from Goldman Sachs Conviction Buy List.
Saks (SKS) Raised to Buy at Deutsche Bank.
Sonic Solutions (SNIC) Raised to Outperform at William Blair.
Vical (VICL) Started as Overweight at Thomas Weisel.

JON C. OGG

Posted on: June 12, 2009 – 6:31 am in Analyst Calls, , , , , , , , , ,

Speculative Swine Flu Stocks Make Last Stand (NVAX, GNBT, BCRX, PURE, VICL, VIVO, AVII)

It looks like everyone has figured out that swine flu was more of a media pandemic rather than a disease or viral pandemic.  Had this been November as flu season was starting, that might have been a bigger deal.  We have seen substantial pullbacks after the massive gains seen in the speculative swine flu stocks.  Novavax, Inc. (NASDAQ: NVAX), Generex Biotechnology Corp. (NASDAQ: GNBT), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Pure Bioscience (NASDAQ: PURE), Vical Inc (NASDAQ: VICL), Meridian Bioscience Inc. (NASDAQ: VIVO), and AVI BioPharma Inc. (NASDAQ: AVII) have all begun their overbought roll-over.
Read More »

Posted on: May 5, 2009 – 3:12 pm in Biotech, Trading Alert, , , , , , ,

Speculative Swine Flu Stocks Giving It Back (NVAX, GNBT, BCRX, PURE, VICL, VIVO, AVII)

burning-money-pic32This week there have been many crazy stock gains among the speculative biotech sector, and these were tied directly to the ’speculative stocks’ that could have any ties in reality, fiction, and even imagination to a cure or hope in the fight against Swine Flu or any other sort of flu for that matter.

As you will see below, Novavax, Inc. (NASDAQ: NVAX), Generex Biotechnology Corp. (NASDAQ: GNBT), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Pure Bioscience (NASDAQ: PURE), Vical Inc (NASDAQ: VICL), Meridian Bioscience Inc. (NASDAQ: VIVO), and AVI BioPharma Inc. (NASDAQ: AVII) have all begun their overbought roll-over.
Read More »

Posted on: April 29, 2009 – 10:23 am in Biotech, Trading Alert, , , , , , ,

Swine Flu Lessons from SARS, Mad Cow & Bird Flu of Past (GILD, BCRX, NVAX, GNBT, VICL, AVII, CRXL, RHHBY, GSK, SFD, EWW, MXF)

burning-money-pic27Monday is looking like a SWINE FLU speculative flu stock stock bonanza, and we want to caution about some of the lessons of scares in the past of SARS, bird flu, Mad Cow, and even hoof & mouth as similar references.  The two approved drug treatments, not vaccines, which are being released are Tamiflu made by Roche (OTC: RHHBY) and Relenza made by GlaxoSmithkline (NYSE: GSK).  Gilead Sciences, Inc. (GILD) gets royalties from Roche for Tamiflu, and its shares are indicated north of $48.00 after a $45.80 close on Friday.  There are also waves of tier-two and tier-three stocks which could move on this news, but be advised that we have seen these pops in the past from SARS and Bird Flu which were followed ultimately by lower share prices and many of the speculative players disappeared.

Of the tier-two stocks, you have BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) and Novavax, Inc. (NASDAQ: NVAX).  Of the tier-three stocks you have Generex Biotechnology Corp. (NASDAQ: GNBT), Vical Inc. (NASDAQ: VICL), AVI Biopharma, Inc. (NASDAQ: AVII), and Crucell NV (NASDAQ: CRXL).  More descriptive data has been provided for each move.   On another scale, Smithfield Foods Inc. (NYSE: SFD), the iShares MSCI Mexico Investable Market Index (NYSE: EWW), and The Mexico Fund, Inc. (NYSE: MXF) have exposure here as well.
Read More »

Posted on: April 27, 2009 – 6:40 am in Biotech, Drug companies, Food, Medical, Pharmaceuticals, Regulation, Research, Trading Alert, , , , , , , , ,

Vical $2 Million NIH Grant For Herpes Vaccine (VICL)

Vical, Incorporated (NASDAQ: VICL) has been awarded a $2 million Phase II small business technology transfer grant from the US National Institute of Allergy and Infectious Diseases department from the National Institues of Health.

The grant is to fund an ongoing development of Vical’s plasmid DNA vaccine against Herpes simplex virus type 2.  This is none other than the sexually transmitted virus that causes genital herpes.

Research is being conducted at the University of Wasington and the University of Texas. The goal of the study is to be used in people who already have HSV-2 with a primary goal of reducing or eliminating periodic herpes viral flare-ups and the associated viral shedding and transmission.

The potential list of users could be tens of millions and there is currently no such vaccine or drug that is a true cure for this.

Vical’s market cap is a mere $146 million.

Jon C. Ogg
April 3, 2008

Posted on: April 3, 2008 – 7:24 am in Biotech,

Pre-Market Stock News (June 18, 2007)

(AA) An ALCOA bid from BHP may be kindled according to numerous M&A reports.
(ADVNA) Advanta trades ex-split to reflect a 3-2 stock split.
(AGU) Agrium said earnings will be at or above the upper end of its $1.45 to $1.55 range.
(BBI) Blockbuster is going to favor the Blu-Ray HD discs.
(BNHNA) Benihana $0.35 EPS vs $0.30e.
(BWLD) Buffalo Wild Wings trades ex-split to reflect a 2-1 stock split.
(CEPH) Cephalon received FDA Marketing approval of Nuvigil for excessive sleepiness.
(CVTX) CV Therapeutics traded up on Cramer recommendation.
(DJ) Dow Jones may get a rival bid from Pearson and General Electric.
(ECIL) ECI Telecom in discussions for potential takeovers at $10.00 per share.
(ENCY) Encysive Pharma trading down 50%; announced third ‘approvable’letter from FDA for Thelin for treating pulmonary arterial hypertension, but it did not demonstrate the evidence of effectiveness needed for approval and may have to drastically cut costs.
(ESC) Emeritus Corp announces a 10.5 million share common stock offering; 9 million shares were from the company and 1.5 million from selling shareholders.
(FRN) Friendly Ice Cream going private at $15.50.
(FTEK) Fuel-Tech gets two orders totaling $2 million.
(GCO) Genesco gets $54.50 per share offer and buyout from Finish Line.
(KERX) Keryx Bio announced its CFO is resigning.
(LXRX) Lexicon Pharma secured a major investment in the company as a two part investment: $205 million and $60 million.
(MSFT) Microsoft making investment in Chinese television and media makers to change IPTV to Mediaroom.
(NVDA) NVIDIA noted as speculative chip play by Cramer.
(OBAS) Optibase won encoder pact from Huawei for IPTV.
(PAY) Verifone announced a $275 million senior convertible note offering.
(THRM) Thermage says FDA clears indication for Thermacool system.
(VICL) Vical licensee AnGes MG announces positive results of Phase 3 angiogenesis trial in Japan.
(VRAZ) Veraz platform chosen by Golden Telecom for an upgrade of its TDM network to a next-generation network.
(XFML) Xinhua Finance Media wins contract to re-brand Hebei Movie & Drama TV channel.

Jon C. Ogg
June 18, 2007

Posted on: June 18, 2007 – 6:53 am in Pre-Market Activity, , , , , , , , , , , , , , , , , , , , , , , , ,